Patents Examined by Carol A. Spiegel
-
Patent number: 6326136Abstract: Conjugate probes are prepared in a one step process by incubating a macromolecule and a labeling group with an unsaturated polyaldehyde as the conjugating agent. The conjugating agent is capable of bonding virtually any labeling group to a macromolecule. Conjugate probes have been shown to have a high degree of specificity and exhibit a strong signal with minimal background.Type: GrantFiled: December 23, 1994Date of Patent: December 4, 2001Assignee: Digene CorporationInventors: James G. Lazar, Floyd E. Taub
-
Patent number: 6124107Abstract: A immunoassay based on the detection of leukocyte-elastase produced fibrinogen cleavage peptides which allows the evaluation of the potency of compounds that inhibit formation of cleavage peptides in a variety of in vitro cell biological situations is provided. The assay may be employed to detect an endogenous leukocyte-elastase produced fibrinogen cleavage peptide signal in normal human plasma and at elevated levels in cystic fibrosis plasma and in rheumatoid arthritis synovial fluid samples. The assay procedure can be a single step assay which allows for the rapid and reproducible detection of specific cleavage peptides.Type: GrantFiled: June 6, 1995Date of Patent: September 26, 2000Assignee: Merck & Co., Inc.Inventors: John L. Humes, Richard Allen Mumford, D. T. Philip Davies, Mary Ellen Dahlgren, Joshua Schafer Boger
-
Patent number: 6090568Abstract: A multilayer dry immunoassay element comprising 1) a spreading layer having a sample application area and a signal read area and 2) a separate receptor layer residing on 3) a radiation-transmissive support characterized in that the spreading layer contains a light absorbing material.Type: GrantFiled: August 4, 1997Date of Patent: July 18, 2000Assignee: Clinical Diagnostic Systems, Inc.Inventors: Richard Troconis Belly, Caroline Erdrich, Richard Calvin Sutton
-
Patent number: 6074837Abstract: An assay method that requires a soluble fibrin monomer or a soluble fibrin monomer reagent as one of the components of the assay. The reagent is a fibrin-like material having a solubility and stability similar to fibrinogen in that it remains soluble and stable at physiological conditions at a concentration employed in the assay in the absence of fibrin polymerization inhibitors or reagents for maintaining solubility.Type: GrantFiled: June 6, 1995Date of Patent: June 13, 2000Assignee: New York Blood Center, Inc.Inventors: Roman Procyk, Bohdan J. Kudryk
-
Patent number: 6022682Abstract: An article for detecting thermostable nuclease positive, potentially enterotoxigenic, staphylococci, containing unhydrolyzed nucleotides, toluidine blue O, and a binder, wherein the article is adapted for placement against a sample suspected of containing enterotoxigenic staphylococci. A method of detecting thermostable nuclease positive staphylococci in a sample utilizing the article, and a kit for the detection of thermostable nuclease positive staphylococci containing the article, are also described.Type: GrantFiled: August 14, 1996Date of Patent: February 8, 2000Assignee: Minnesota Mining and Manufacturing CompanyInventors: Patrick A. Mach, Marlys E. Lund
-
Patent number: 5972721Abstract: An apparatus and method for immunomagnetic separation and concentration of target biological materials is disclosed. The immunomagnetic separation is performed by a magnetic flow cell, or filter block, as part of an automated mostly continuous immunomagnetic assay system. The magnetic flow cell has two bundles of ferromagnetic rods or pins positioned inside an internal chamber so that a fluid sample flowing through the flow cell passes through the pins. A pair of cobalt magnets flank the flow cell so that the pins concentrate and sufficiently increase the magnetic fields so that even nanometer size magnetic beads can be captured. The overall system combines a reaction subsystem for reacting coated magnetic beads with a sample, a collection subsystem for capturing magnetic beads, a rinsing subsystem for removing debris and a filtering subsystem for removing captured magnetic beads from the collection subsystem. The new magnetic flow filter is the key component for the collection and filtering subsystems.Type: GrantFiled: March 14, 1997Date of Patent: October 26, 1999Assignee: The United States of America as represented by the Secretary of the Air ForceInventors: John G. Bruno, Johnathan L. Kiel, John P. Kilian
-
Patent number: 5968758Abstract: Antibodies having binding affinity for free IGFBP-1, biological compositions including antibodies having binding affinity for free IGFBP-1, kits for detecting free IGFBP-1 using the antibodies, and cell lines for producing the antibodies are provided. Also provided are devices and methods for detecting free IGFBP-1 and a rupture in a fetal membrane based on the presence of amniotic fluid in a vaginal secretion, as indicated by the presence of free IGFBP-1 in the vaginal secretion. The antibodies that are provided may be characterized by their ability to selectively recognize those IGFBP-1 molecules which are free of IGF-1 and IGF-2, i.e., antibodies which have a binding affinity for free IGFBP-1 that is greater than a binding affinity of the antibody to bound IGFBP-1. These antibodies may also be characterized by their competition with IGF-1 and IGF-2 for binding to IGFBP-1.Type: GrantFiled: October 28, 1996Date of Patent: October 19, 1999Assignee: California Research LLCInventors: Boris Fuks, Marina Boltovskaya, Alexander Konstantinov, Svetlana Nazimova, Nelli Starosvetskaya, Alexander Stepanov, Evgeny Zaraisky
-
Patent number: 5955074Abstract: This invention is directed to a Directed Human Immoglobulin and compositions thereof for preventing or treating staphylococcal infections such as S. epidermidis in neonates.Type: GrantFiled: June 2, 1995Date of Patent: September 21, 1999Assignee: Henry M. Jackson Foundation for the Advancement of Military MedicineInventor: Gerald W. Fischer
-
Patent number: 5948627Abstract: The present invention provides an improved method for detection of panel reactive antibodies in serum of a subject against HLA class I antigens, which comprises the steps of adding serum from a subject to an array of microbeads, each microbead presenting HLA antigens from a cell population presenting the same HLA antigens; incubating the serum and microbeads for sufficient time for anti-HLA antibodies in the serum to bind to the HLA antigens presented on the microbeads; removing the serum components which do not specifically bind with the HLA antigens presented on the microbeads; incubating the microbeads with a labeled ligand capable of specifically binding with anti-HLA antibodies bound to said HLA antigens; removing the labeled ligand which is not bound to said HLA antigens; and detecting the presence of labeled ligand bound to said HLA antigens by flow cytometry.Type: GrantFiled: May 30, 1997Date of Patent: September 7, 1999Assignee: One LambdaInventors: Jar-How Lee, Rui Pei
-
Patent number: 5942444Abstract: In general, the invention features a method of marking a product for identification in which a marker, composed of a print molecule, print molecule analogue, or molecularly imprinted molecule, are added to the product and subsequently measured in a specific binding assay.Type: GrantFiled: January 27, 1997Date of Patent: August 24, 1999Assignee: Biocode, Inc.Inventors: James H. Rittenburg, Robin Jenkins
-
Patent number: 5939252Abstract: An assay device for detection or determination of an analyte in a sample uses either removably attachable components or hinged panels to provide greater flexibility and reduce manufacturing and storage costs. In one embodiment of the device, the device comprises: (1) a first opposable component including:(a) a first panel; (b) a second panel mounted on the first panel generally parallel to the first panel with space between the first and second panel, the second panel having an opening forming a first receptacle for a sample collection device; and (c) a second receptacle for a test strip formed by the first panel and the second panel; and (2) a second opposable component hingedly attached to the first opposable component. In this device, the first and second opposable components can be brought into operable contact so that fluid is expressed from the sample collection device and applied to the test strip for detection or determination of an analyte by a test performed on the test strip.Type: GrantFiled: May 9, 1997Date of Patent: August 17, 1999Inventors: Donald J. Lennon, Roger N. Piasio
-
Patent number: 5939331Abstract: A method and device for detecting the presence, absence or amount of an analyte in a whole blood sample is disclosed. The device comprises four zones, a sample receiving zone, a labeling zone, a capture zone and an absorbent zone. The sample receiving zone contains an irreversibly immobilized reagent that allows for removal of substantially all red blood cells from the whole blood sample. Flow through the device is via capillary migration and all of the dissolved or dispersed components in the sample flow at substantially equal rates and with relatively unimpaired flow through the device. The method involves the use of the device for detection of analyte in a whole blood sample.Type: GrantFiled: May 21, 1993Date of Patent: August 17, 1999Assignee: Quidel CorporationInventors: John Burd, Steven Miller, Gerald Rowley, Allan Pronovost
-
Patent number: 5932704Abstract: Antibodies capable of binding to the a subunit of the human GM-CSF receptor are described. These antibodies can inhibit the proliferation of cells whose growth is dependent upon the presence of human GM-CSF. Methods of assaying for the human GM-CSF receptor are also disclosed.Type: GrantFiled: January 25, 1995Date of Patent: August 3, 1999Assignee: Dana-Farber Cancer InstituteInventor: Paul T. Jubinsky
-
Patent number: 5932483Abstract: The invention provides a fragment of C1q which is characterized in that a plurality of such fragments selectively binds immune complexes or aggregated immunoglobulins in the presence of monomeric immunoglobulin. The invention also provides a synthetic peptide comprising the sequence:Leu Glu Gln Gly Glu Asn Val Phe Leu Gln Ala Thr 1 5 10 ?SEQ ID NO 2!or variants thereof capable of binding immunoglobulin. Like the C1q fragment, a plurality of the peptides can selectively bind immune complexes or aggregated immunoglobulins in the presence of monomeric immunoglobulin. As a result of this property, the fragments and peptides are well-adapted for removing immune complexes and aggregated immunoglobulins from fluids containing monomeric immunoglobulin, and for detecting or quantitating immune complexes in such fluids. The invention also provides a binding material for removing immune complexes or aggregated immunoglobulins from a fluid.Type: GrantFiled: April 5, 1996Date of Patent: August 3, 1999Assignee: Northwestern UniversityInventors: Michael A. Baumann, Byron E. Anderson, Jonathan P. Fryer
-
Patent number: 5928886Abstract: The present invention relates to a dry immunoassay analytical element for assaying a ligand, comprising a support bearing: (a) a label zone comprising an enzyme labeled ligand or an enzyme labeled receptor; (b) a spreading zone; (c) a receptor zone comprising a fixed concentration of an immobilized receptor for the ligand; and (d) a gravure zone comprising a diaryl telluride. A prefered embodiment of the present invention further comprises a vanadyl salt. The present invention further relates to a method for performing an assay using an element as described above.Type: GrantFiled: September 23, 1997Date of Patent: July 27, 1999Assignee: Johnson & Johnson Clinical Diagnostics, Inc.Inventors: Margaret Elizabeth Logan, Janet Fyles, Stephen Hasselberg
-
Patent number: 5925533Abstract: A conjugate consisting of a sequence of the analyte and an antibody against one of the antibodies used in the test can be employed, in aqueous solution and in precisely known quantity, as a stable calibrator in a sandwich immunoassay for detecting the analyte.Type: GrantFiled: December 13, 1996Date of Patent: July 20, 1999Assignee: Bayer AktiengesellschaftInventors: Margit Doth, Christoph Petry, Nicole Petesch
-
Patent number: 5922615Abstract: Devices for use in heterogeneous ligand-receptor assays, having a porous member in contact with a nonabsorbent textured surface, where the surface texturing is such that a capillary network is formed when in fluid communication with the porous member. More particularly, these devices comprise:(a) a porous member having (i) at least one binding agent capable of immobilizing at least one target ligand on the porous member from a fluid sample in at least one zone and (ii) a means for detecting the presence or amount of said target ligand as a result of the assay process; and(b) a nonabsorbent member in fluid communication with the porous member, the nonabsorbent member forming at least one capillary with the porous member so that when sample, alone or in combination with other fluids, is added to the porous member, fluid is drawn through the porous member.Type: GrantFiled: June 2, 1995Date of Patent: July 13, 1999Assignee: Biosite Diagnostics IncorporatedInventors: Mark R. Nowakowski, Kenneth F. Buechler, Richard R. Anderson, Gunars E. Valkirs
-
Patent number: 5916746Abstract: This invention relates to an improved method for detecting and quantifying the presence of a target molecule, such as an antigen, an antibody or a polynucleotide, in a sample which method uses alkaline phosphatase as the reporter enzyme and the reduction of a tetrazolium salt to a formazan as part of the detection/signaling system.Type: GrantFiled: May 9, 1996Date of Patent: June 29, 1999Assignee: Kirkegaard & Perry Laboratories, Inc.Inventors: Carrington S. Cobbs, Thomas M. Woerner
-
Patent number: 5895765Abstract: Disclosed is an improved method for the detection of an analyte in a fluid test sample using a strip of a negatively charged matrix material having a zone containing mobile, labeled binding partner for the analyte and a separate zone for capturing the labeled binding partner as it is carried through this zone by the fluid test sample. The improvement involves combining the fluid test sample with a polyalkoxylated amine surfactant to control non-specific binding of the labeled binding partner to the negatively charged matrix material.Type: GrantFiled: June 30, 1997Date of Patent: April 20, 1999Assignee: Bayer CorporationInventors: Gary W. Rheinheimer, Meitak Teresa Yip
-
Patent number: 5891722Abstract: Antibodies having binding affinity for free IGFBP-1, biological compositions including antibodies having binding affinity for free IGFBP-1, kits for detecting free IGFBP-1 using the antibodies, and cell lines for producing the antibodies are provided. Also provided are devices and methods for detecting free IGFBP-1 and a rupture in a fetal membrane based on the presence of amniotic fluid in a vaginal secretion, as indicated by the presence of free IGFBP-1 in the vaginal secretion. The antibodies that are provided may be characterized by their ability to selectively recognize those IGFBP-1 molecules which are free of IGF-1 and IGF-2, i.e., antibodies which have a binding affinity for free IGFBP-1 that is greater than a binding affinity of the antibody to bound IGFBP-1. These antibodies may also be characterized by their competition with IGF-1 and IGF-2 for binding to IGFBP-1.Type: GrantFiled: October 28, 1996Date of Patent: April 6, 1999Assignee: California Research LLCInventors: Boris Fuks, Marina Boltovskaya, Alexander Konstantinov, Svetlana Nazimova, Nelli Starosvetskaya, Alexander Stepanov, Evgeny Zaraisky